M. Lark

发表

A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine

Guodong Liu, Catherine Yuan, J. Violin, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers

Lynn R. Webster, J. Violin, L. Webster, 2014, PAIN®.

Injurious mechanical compression of bovine articular cartilage induces chondrocyte apoptosis.

A. Grodzinsky, E. Frank, A. Badger, 2000, Archives of biochemistry and biophysics.

Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.

K. Ward, K. Erhard, R. Calvo, 2000, Journal of medicinal chemistry.

Glial hyaluronate-binding protein: a product of metalloproteinase digestion of versican?

William Arbuthnot Sir Lane, M. Lark, A. Bignami, 1995, The Biochemical journal.

A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.

D. Veber, S. Kumar, D. Yamashita, 2007, Bone.

Identification and in vivo efficacy of small-molecule antagonists of integrin αvβ3 (the vitronectin receptor)

R. Willette, R. Keenan, M. Lark, 2000 .

Antagonism of the Osteoclast Vitronectin Receptor with an Orally Active Nonpeptide Inhibitor Prevents Cancellous Bone Loss in the Ovariectomized Rat

K. Ward, B. R. Smith, M. Lark, 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Down‐regulation of chondrocyte aggrecan and type‐II Collagen gene expression correlates with increases in static compression magnitude and duration

P. Ragan, A. Grodzinsky, A. Badger, 1999, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Cartilage matrix metabolism in osteoarthritis: markers in synovial fluid, serum, and urine.

H. Roos, L. Lohmander, M. Lark, 1992, Clinical biochemistry.

Differential effects of IL-1 and TNF alpha on the expression of stromelysin, collagenase and their natural inhibitor, TIMP, in rheumatoid human synovial fibroblasts.

M. Lark, M. Tocci, K. Macnaul, 1992, Matrix (Stuttgart, Germany). Supplement.

Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury.

N. Bhardwaj, M. Lark, L. Walakovits, 1992, Arthritis and rheumatism.

Differential in vivo expression of collagenase messenger RNA in synovium and cartilage. Quantitative comparison with stromelysin messenger RNA levels in human rheumatoid arthritis and osteoarthritis patients and in two animal models of acute inflammatory arthritis.

M. Lark, K. Macnaul, F. Buechel, 1993, Arthritis and rheumatism.

Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion.

P. Libby, Z. Galis, M. Lark, 1994, Circulation research.

Inhibition of caspase‐3‐like activity prevents apoptosis while retaining functionality of human chondrocytes in vitro

A. Badger, M. Goldring, M. Lark, 2000, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis.

L. Lohmander, M. Lark, L. A. Hoerrner, 1993, Arthritis and rheumatism.

Markers of cartilage matrix metabolism in human joint fluid and serum: the effect of exercise.

E. Thonar, H. Roos, L. Lohmander, 1995, Osteoarthritis and cartilage.

Proteoglycan degradation after injurious compression of bovine and human articular cartilage in vitro: interaction with exogenous cytokines.

P. Patwari, A. Cole, A. Grodzinsky, 2003, Arthritis and rheumatism.

GPCR biased ligands as novel heart failure therapeutics.

J. Violin, M. Lark, D. Soergel, 2013, Trends in cardiovascular medicine.

Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage.

M. Lark, J. Sandy, C. Flannery, 1992, The Journal of biological chemistry.

Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis.

J. Weidner, J. Mudgett, M. Lark, 1997, Osteoarthritis and cartilage.

Potent and Selective Inhibition of Human Cathepsin K Leads to Inhibition of Bone Resorption In Vivo in a Nonhuman Primate

Y. Ru, D. Veber, K. Erhard, 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Beta-arrestin-biased ligands at the AT1R: a novel approach to the treatment of acute heart failure

J. Violin, M. Lark, D. Soergel, 2012 .

Inhibition of cartilage degradation and changes in physical properties induced by IL-1beta and retinoic acid using matrix metalloproteinase inhibitors.

L. Bonassar, A. Grodzinsky, E. Frank, 1997, Archives of biochemistry and biophysics.

In vivo effects of stromelysin on the composition and physical properties of rabbit articular cartilage in the presence and absence of a synthetic inhibitor.

L. Bonassar, E. Frank, M. Lark, 1995, Arthritis and rheumatism.

Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture.

P. Libby, A. Grodzinsky, R. T. Lee, 1995, Arteriosclerosis, thrombosis, and vascular biology.

A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.

Y. Ru, D. Veber, K. Erhard, 2002, Bone.

Novel bone antiresorptive approaches.

M. Lark, I. James, 2002, Current opinion in pharmacology.

First Clinical Experience With TRV130: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

J. Violin, C. Cowan, M. Lark, 2014, Journal of clinical pharmacology.

Human Osteoclast Cathepsin K Is Processed Intracellularly Prior to Attachment and Bone Resorption

D. Veber, M. Lark, I. James, 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Close and focal contact adhesions of fibroblasts to a fibronectin-containing matrix.

L. Culp, J. Laterra, M. Lark, 1985, Federation proceedings.

Extracellular Matrix Digestion

P. Libby, Z. Galis, M. Lark, 2005 .

Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells.

P. Libby, A. Grodzinsky, D. Vaughan, 1996, Circulation research.

The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface

M. Lark, K. Hellström, I. Hellström, 1986, The Journal of cell biology.

Arterial chondroitin sulfate proteoglycan: localization with a monoclonal antibody.

M. Lark, K. Hellstrom, K. Hellström, 1988, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Blood Vessel Proteoglycans

M. Lark, T. Wight, M. G. Kinsella, 1987 .

Modulation of proteoglycan metabolism by aortic smooth muscle cells grown on collagen gels.

M. Lark, T. Wight, 1986, Arteriosclerosis.

Biased ligands at G-protein-coupled receptors: promise and progress.

J. Violin, M. Lark, D. Soergel, 2014, Trends in pharmacological sciences.

First Clinical Experience with TRV027: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

J. Violin, C. Cowan, M. Lark, 2013, Journal of clinical pharmacology.

Disease-modifying activity of SB 273005, an orally active, nonpeptide αvβ3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis

S. Sarkar, A. Badger, M. Lark, 2001 .

Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin αvβ3) antagonists

K. Ward, R. Willette, T. Yue, 2003 .

Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonist.

M. Lark, S. Hoffman, W. Miller, 2002, The Journal of pharmacology and experimental therapeutics.

Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression.

M. Lark, M. Tocci, K. Macnaul, 1990, The Journal of biological chemistry.

Activation and inhibition of endogenous matrix metalloproteinases in articular cartilage: effects on composition and biophysical properties.

L. Bonassar, A. Hollander, E. Frank, 1996, Archives of biochemistry and biophysics.

Changes in cartilage composition and physical properties due to stromelysin degradation.

L. Bonassar, A. Grodzinsky, D. Eyre, 1995, Arthritis and rheumatism.

Quantification of a matrix metalloproteinase-generated aggrecan G1 fragment using monospecific anti-peptide serum.

Lark, J. Weidner, M. Lark, 1995, The Biochemical journal.

In vivo activity of human recombinant tissue inhibitor of metalloproteinases (TIMP). Activity against human stromelysin in vitro and in the rat pleural cavity.

M. Lark, L. Walakovits, V. Moore, 1990, Biochemical pharmacology.

Cell-mediated Catabolism of Aggrecan

J. Weidner, M. Lark, J. Kimura, 1995, The Journal of Biological Chemistry.

Transport of tissue inhibitor of metalloproteinases‐1 through cartilage: Contributions of fluid flow and electrical migration

A. Grodzinsky, M. Lark, S. Trippel, 1998, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Aggrecan degradation in osteoarthritis and rheumatoid arthritis.

L. Lohmander, M. Lark, E. Bayne, 1995, Acta orthopaedica Scandinavica. Supplementum.

Effects of Matrix Metalloproteinases on Cartilage Biophysical Properties in Vitro and in Vivo a

L. Bonassar, E. Frank, A. Grodzinsky, 1994, Annals of the New York Academy of Sciences.

Human articular chondrocytes produce IL-7 and respond to IL-7 with increased production of matrix metalloproteinase-13

R. Loeser, M. Lark, S. Blake, 2008, Arthritis research & therapy.

Biosynthetic response and mechanical properties of articular cartilage after injurious compression

B Kurz, P. Patwari, A. Grodzinsky, 2001, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Longitudinal and cross-sectional variability in markers of joint metabolism in patients with knee pain and articular cartilage abnormalities.

E. Thonar, L. Ryd, D. Eyre, 1998, Osteoarthritis and cartilage.

CKβ‐8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues

Elizabeth, J. R. White, M. Lark, 2000, Journal of cellular physiology.

Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.

K. Erhard, R. Keenan, M. Lark, 1999, Bioorganic & medicinal chemistry letters.

Interference with Tissue Factor Prolongs Intrahepatic Islet Allograft Survival in a Nonhuman Primate Marginal Mass Model

R. Jordan, C. Ricordi, R. Alejandro, 2007, Transplantation.

TRVO27, A BETA-ARRESTIN BIASED LIGAND AT THE ANGIOTENSIN 2 TYPE 1 RECEPTOR, PRODUCES RAPID, REVERSIBLE CHANGES IN HEMODYNAMICS IN PATIENTS WITH STABLE SYSTOLIC HEART FAILURE

C. Cowan, M. Lark, D. Soergel, 2013 .

Development and Characterization of a Human In Vitro Resorption Assay: Demonstration of Utility Using Novel Antiresorptive Agents

M. Lark, I. James, T. Tomaszek, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Markers of joint tissue turnover in joint fluids from hips with osteonecrosis of the femoral head

Y. Iwamoto, Y. Sugioka, L. Lohmander, 2000, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

In vivo expression of stromelysin in synovium and cartilage of rabbits injected intraarticularly with interleukin-1 beta.

M. Lark, K. Macnaul, N. Hutchinson, 1992, Arthritis and rheumatism.

Recombinant human interleukin-1 beta-induced increase in levels of proteoglycans, stromelysin, and leukocytes in rabbit synovial fluid.

M. Lark, G. Eiermann, I. Singer, 1992, Arthritis and rheumatism.

Musculoskeletal diseases: novel targets for therapeutic intervention

K. Morrison, M. Lark, 2002 .

Heparan sulphate proteoglycan as mediator of some adhesive responses and cytoskeletal reorganization of cells on fibronectin matrices: independent versus cooperative functions.

R. Beyth, L. Culp, J. Laterra, 1986, Ciba Foundation symposium.

Vascular cell proteoglycans: evidence for metabolic modulation.

M. Lark, T. Wight, M. G. Kinsella, 1986, Ciba Foundation symposium.

agonism of the l-opioid receptor by TRV 130 increases analgesia and reduces on-target adverse effects versus morphine : A randomized , double-blind , placebo-controlled , crossover study in healthy

J. Violin, L. Webster, M. Lark, 2014 .

Erratum: Biased ligands at G protein-coupled receptors: promise and progress:[Trends in Pharmacological Sciences 35 (2014) 308-316]

J. Violin, M. Lark, D. Soergel, 2014 .

VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis.

J. Weidner, T. Glant, M. Lark, 1995, The Journal of clinical investigation.

Role of stromelysin-1 in cartilage metabolism

L. Lohmander, M. Lark, E. Bayne, 1999 .

Increased osteoblastogenesis and decreased bone resorption protect against ovariectomy-induced bone loss in thrombospondin-2-null mice.

P. Bornstein, M. Lark, I. James, 2005, Matrix biology : journal of the International Society for Matrix Biology.

Potent and Selective Cathepsin L Inhibitors Do Not Inhibit Human Osteoclast Resorption in Vitro *

Y. Ru, D. Veber, D. Yamashita, 2001, The Journal of Biological Chemistry.

Induction of increased levels of proteoglycan fragments in synovial fluid (SF) and increased levels of stromelysin in cartilage, synovium and SF by intraarticular injection of canine monocyte conditioned medium into dogs.

M. Lark, N. Hutchinson, E. Bayne, 1994, The Journal of rheumatology.

Cartilage metabolism in the injured and uninjured knee of the same patient.

D. Heinegård, H. Roos, L. Lohmander, 1994, Annals of the rheumatic diseases.

Selective solubilization of hyaluronic acid from fibroblast substratum adhesion sites.

L. Culp, M. Lark, 1982, Journal of Biological Chemistry.

Chapter 24. Inhibition of Matrix Metalloproteinases.

J. W. Becker, M. Lark, W. Hagmann, 1996 .

The potential role of fibroblasts in periprosthetic osteolysis: Fibroblast response to titanium particles

J. Galante, T. Glant, K. Mikecz, 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Turnover of heparan sulfate proteoglycans from substratum adhesion sites of murine fibroblasts.

L. Culp, M. Lark, 1984, The Journal of biological chemistry.

Azepanone-based inhibitors of human and rat cathepsin K.

Y. Ru, D. Veber, K. Ward, 2001, Journal of medicinal chemistry.

Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.

Baoguang Zhao, M. Head, D. Veber, 2006, Journal of medicinal chemistry.

Production, purification and characterization of canine prostromelysin.

M. Lark, P. Cameron, K. Macnaul, 1992, Matrix.

Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage.

D. Eyre, L. Chun, M. Lark, 1991, The Journal of biological chemistry.

The fibronectin cell attachment sequence Arg-Gly-Asp-Ser promotes focal contact formation during early fibroblast attachment and spreading

M. Lark, I. Singer, D. Kawka, 1987, The Journal of cell biology.

Apoptosis and inflammatory disease: osteoarthritis

M. Lark, M. Nuttall, M. Gowen, 1999 .

Modification of proteoglycans during maturation of fibroblast substratum adhesion sites.

L. Culp, M. Lark, 1983, Biochemistry.

Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.

J. Weidner, L. Lohmander, M. Lark, 1997, The Journal of clinical investigation.

Temporal patterns of stromelysin‐1, tissue inhibitor, and proteoglycan fragments in human knee joint fluid after injury to the cruciate ligament or meniscus

H. Roos, M. Lark, L. Dahlberg, 1994, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments in human knee joint fluid after injury.

H. Roos, L. Lohmander, M. Lark, 1993, The Journal of rheumatology.

Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.

P. Libby, Z. Galis, M. Lark, 1994, The Journal of clinical investigation.

Cardiorenal Actions of TRV120027, a Novel ß-Arrestin–Biased Ligand at the Angiotensin II Type I Receptor, in Healthy and Heart Failure Canines: A Novel Therapeutic Strategy for Acute Heart Failure

J. Violin, E. Whalen, M. Lark, 2011, Circulation. Heart failure.

Potent and Selective Nonpeptide Inhibitors of Caspases 3 and 7 Inhibit Apoptosis and Maintain Cell Functionality*

J. Adams, C. Debouck, M. Head, 2000, The Journal of Biological Chemistry.

Mechanical injury potentiates proteoglycan catabolism induced by interleukin-6 with soluble interleukin-6 receptor and tumor necrosis factor alpha in immature bovine and adult human articular cartilage.

Xiao-Yu Song, Alan J. Grodzinsky, Anna Plaas, 2009, Arthritis and rheumatism.

Comparison of the proteoglycanolytic activities of human leukocyte elastase and human cathepsin G in vitro and in vivo.

M. Lark, M. Poe, V. Moore, 1993, Connective tissue research.

PRODUCTION AND PURIFICATION OF PROSTROMELYSIN AND PROCOLLAGENASE GINGIVAL FIBROBLASTS FROM IL-1 BETA-STIMULATED HUMAN

M. Lark, T. Shah, Tsau-Yen Lin, 1990 .

Production and purification of prostromelysin and procollagenase from IL-1 beta-stimulated human gingival fibroblasts.

T. Lin, M. Lark, T. Shah, 1990, Connective tissue research.

Sensitivity of monoclonal antibody, 5-D-4, for the detection of aggrecan, aggrecan fragments, and keratan sulfate

M. Lark, V. Moore, C. Saphos, 2005, Agents and Actions.

Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.

K. Erhard, B. R. Smith, M. Lark, 1999, Journal of Pharmacology and Experimental Therapeutics.

Multiple classes of heparan sulfate proteoglycans from fibroblast substratum adhesion sites. Affinity fractionation on columns of platelet factor 4, plasma fibronectin, and octyl-sepharose.

L. Culp, M. Lark, 1984, The Journal of biological chemistry.

SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes.

S. Kumar, F. Barone, A. Badger, 1998, Journal of immunology.

Cartilage-Derived Chondrocytes Inducible Nitric Oxide Synthase in Bovine Protein Kinase , Nitric Oxide Production , and SB 203580 Inhibits p 38 Mitogen-Activated

F. Barone, A. Badger, A. H. Nelson, 1998 .

Design of potent and selective human cathepsin K inhibitors that span the active site.

J G Gleason, S. Carr, R. DesJarlais, 1997, Proceedings of the National Academy of Sciences of the United States of America.

TRV120027, a Novel &bgr;-Arrestin Biased Ligand at the Angiotensin II Type I Receptor, Unloads the Heart and Maintains Renal Function When Added to Furosemide in Experimental Heart Failure

J. Violin, M. Lark, D. Soergel, 2012, Circulation. Heart failure.

TRV120027, a Novel Beta-Arrestin Biased Ligand at the Angiotensin II Type I Receptor, Unloads the Heart and Maintains Renal Function When Added to Furosemide in Experimental Heart Failure

M. Lark, D. Soergel, J. Burnett, 2011 .

Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture.

F J Schoen, P. Libby, F. Schoen, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Selectively Engaging β-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance

Lisa Nguyen, J. Violin, L. Nguyen, 2010, Journal of Pharmacology and Experimental Therapeutics.

Mechanisms and kinetics of glycosaminoglycan release following in vitro cartilage injury.

Alan J Grodzinsky, P. Patwari, A. Grodzinsky, 2004, Arthritis and rheumatism.

The role of molecular markers to monitor disease, intervention and cartilage breakdown in osteoarthritis.

H. Roos, L. Lohmander, M. Lark, 1995, Acta orthopaedica Scandinavica. Supplementum.

A longitudinal study of cartilage matrix metabolism in patients with cruciate ligament rupture--synovial fluid concentrations of aggrecan fragments, stromelysin-1 and tissue inhibitor of metalloproteinase-1.

H. Roos, L. Lohmander, M. Lark, 1994, British journal of rheumatology.

FUNCTIONS FOR FIBRONECTIN, HYALURONATE, AND HEPARAN PROTEOGLYCANS IN SUBSTRATUM ADHESION OF FIBROBLASTS

L. Culp, J. Laterra, M. Lark, 1982 .

Specialized transduction with lambda plac5: dependence on recA and on configuration of lac and att lambda

M. Lark, R. Porter, K. Low, 1981, Journal of Virology.

TRV0109101, a G Protein-Biased Agonist of the µ-Opioid Receptor, Does Not Promote Opioid-Induced Mechanical Allodynia following Chronic Administration

J. Violin, D. Rominger, C. Cowan, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Cardiorenal Actions of TRV 120027 , a Novel ß-Arrestin – Biased Ligand at the Angiotensin II Type I Receptor , in Healthy and Heart Failure Canines A Novel Therapeutic Strategy for Acute Heart Failure

J. Violin, E. Whalen, M. Lark, 2011 .

PMN elastases: a comparison of the specificity of human isozymes and the enzyme from other species toward substrates and inhibitors.

M. Lark, W. Hagmann, A. Maycock, 1991, Archives of biochemistry and biophysics.

Inhibition of interleukin-1-induced proteoglycan degradation and nitric oxide production in bovine articular cartilage/chondrocyte cultures by the natural product, hymenialdisine.

A. Badger, M. Lark, B. Swift, 1999, The Journal of pharmacology and experimental therapeutics.

Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis.

S. Sarkar, A. Badger, M. Lark, 2001, Arthritis and rheumatism.

Down‐regulation of chondrocyte aggrecan and type‐II Collagen gene expression correlates with increases in static compression magnitude and duration

P. Ragan, A. Grodzinsky, A. Badger, 1999, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

In vitro models for investigation of the effects of acute mechanical injury on cartilage.

A. Kerin, P. Patwari, A. Grodzinsky, 2001, Clinical orthopaedics and related research.

Biased ligands at G-protein-coupled receptors: promise and progress.

M. Lark, D. Soergel, Jonathan D. Violin, 2014, Trends in pharmacological sciences.

Configuration of lac and attX

M. Lark, R. Porter, K. Brooks, 2022 .